KYMR · Kymera Therapeutics, Inc.
$114.84
+3.68% last session
End-of-day data · close of 2026-10-26
Market cap
$9B
Enterprise value
$9B
Trailing P/E
—
Forward P/E
-21.7
Dividend yield
0.0%
Beta
1.98
Avg volume
1M
Employees
0K
Daily Change %
3.68%
5 Days Change
5.79%
10 Days Change
3.91%
30 Days Change
-4.00%
60 Days Change
-8.43%
Month to Day Change
0.66%
Year to Day Change
42.46%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — KYMR
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-09
Latest call per bank · past 12 months
Citigroup
Buy$150
+35.4% vs priceBank of America
Buy$144
+30.0% vs priceWells Fargo
Overweight$151
+36.3% vs priceBarclays
Overweight$139
+25.5% vs priceDeutsche Bank
Hold$120
+8.3% vs priceRBC Capital
Sector Perform$115
+3.8% vs priceUBS
Buy$128
+15.6% vs priceJP Morgan
Overweight$125
+12.9% vs priceJefferies
Buy$122
+10.1% vs priceMorgan Stanley
Overweight$127
+14.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-09 | Raymond James | Initiates | Outperform | $0.00 → $140 |
| 2026-10-05 | Citigroup | Maintains | Buy | $135 → $150 |
| 2026-09-22 | Stifel | Maintains | Buy | $132 → $152 |
| 2026-09-14 | Bank of America | Maintains | Buy | $123 → $144 |
| 2026-09-10 | Wolfe Research | Upgrade | Peer Perform → Outperform | $0.00 |
| 2026-08-31 | Guggenheim | Maintains | Buy | $135 → $170 |
| 2026-08-27 | Wells Fargo | Maintains | Overweight | $116 → $151 |
| 2026-08-06 | Barclays | Maintains | Overweight | $133 → $139 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 56 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 0.1% below the 50-day MA ($114.96).
- bullish: Price vs 200-day MA: Trading 20.3% above the 200-day MA ($95.46).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.77) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($58.56) and high ($127.31).
KYMR Price Chart
Loading chart for KYMR…
Fundamentals
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.